Forty Seven is a biotechnology company that discovers and develops immuno-oncology therapies for the treatment of cancer.
Business Model:
Revenue: $15.7M
Employees: 51-200
Forty Seven, Inc. was acquired by
Gilead Sciences.
The acquisition happend on 2020-03-02.
Details of the transaction were not public
Address: 1490 O'Brien Drive
City: Menlo Park
State: CA
Zip: 94025
Country: US
Forty Seven is a biotechnology company that discovers and develops immuno-oncology therapies for the treatment of cancer.
Contact Phone:
+16503524150
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
6/27/2018
IPO Valuation:
$479M
Ticker Symbol:
FTSV
IPO Price:
$16/share
Amount Raised:
$112M
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|